Assessment of Ability of Breath Hold for Left-sided Breast Cancer Radiation Therapy to Reduce Side Effects to Heart
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01849614|
Recruitment Status : Completed
First Posted : May 8, 2013
Last Update Posted : May 12, 2016
|Condition or disease||Intervention/treatment|
|Breast Cancer||Other: Cardiac SPECT perfusion scan|
|Study Type :||Observational|
|Actual Enrollment :||25 participants|
|Official Title:||Prospective Pilot Study of Assessment of Breath Hold as a Means to Mitigate the Risk of Radiation-associated Reductions in Regional Cardiac Perfusion in Patients With Left-sided Breast Cancer|
|Study Start Date :||March 2013|
|Actual Primary Completion Date :||March 2016|
|Actual Study Completion Date :||March 2016|
Women with left-sided breast cancer
Other: Cardiac SPECT perfusion scan
A SPECT cardiac perfusion scan provides a three-dimensional map of blood flow to the heart tissue. The scan will be taken at rest only.
- Changes in cardiac perfusion [ Time Frame: 6-months post radiation ]Cardiac perfusion will be assessed using SPECT cardiac perfusion scans pre- and 6 months post-radiation. Any post-radiation summed-rest score (SRS) > 0 will be counted as a perfusion defect in the calculation of the perfusion defect rate.
- Wall-motion abnormalities [ Time Frame: 6-months post-treatment ]The incidence of wall-motion abnormalities will be assessed using SPECT in the same 12 segment scoring system used to quantify perfusion. Wall-motion abnormalities will be recorded as present or absent in each cardiac segment. When present, wall-motion abnormalities wil be classified as gypokinetic, akinetic, or dyskinetic. The extent of wall involvement (small or large portion) will be described as mild or severe.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01849614
|United States, North Carolina|
|University of North Carolina at Chapel Hill, Department of Radiation Oncology|
|Chapel Hill, North Carolina, United States, 27599|
|Principal Investigator:||Timothy M Zagar, MD||University of North Carolina, Chapel Hill|